Fate Therapeutics Inc. (FATE)

8.76
NASDAQ : Health Technology
Prev Close 8.11
Day Low/High 8.17 / 8.90
52 Wk Low/High 2.52 / 9.78
Avg Volume 567.80K
Exchange NASDAQ
Shares Outstanding 52.40M
Market Cap 408.73M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

Commit To Purchase Fate Therapeutics At $5, Earn 20% Annualized Using Options

Investors eyeing a purchase of Fate Therapeutics Inc shares, but cautious about paying the going market price of $6.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $5 strike, which has a bid at the time of this writing of 60 cents.

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Fate Therapeutics Announces Issuance Of U.S. Patent Covering Use Of Viral Transduction Enhancers In Gene Therapy

Fate Therapeutics Announces Issuance Of U.S. Patent Covering Use Of Viral Transduction Enhancers In Gene Therapy

Patent Broadly Protects the Use of Prostaglandins for Enhancing Gene Transfer in Blood Stem Cells

Biotech Movers: Fate Shares Spike After Cancer Studies Progress

Biotech Movers: Fate Shares Spike After Cancer Studies Progress

Fate's first subject has been treated with FATE-NK100 for AML and two additional clinical trials of FATE-NK100 for the treatment of multiple advanced solid tumor types will soon open.

TheStreet Quant Rating: D (Sell)